Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03682042
Other study ID # CORDMILK FU
Secondary ID R01HD102967
Status Recruiting
Phase N/A
First received
Last updated
Start date October 17, 2022
Est. completion date June 30, 2027

Study information

Verified date June 2024
Source Nemours Children's Clinic
Contact Zubair H Aghai, MD
Phone 215 955 6523
Email zaghai@nemours.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An extension of the CORDMILK trial, the CORDMILK follow-up trial will evaluate the neurodevelopmental outcomes at 22-26 months age of term/late preterm infants who were non-vigorous at birth and received umbilical cord milking (UCM) or early cord clamping (ECC).


Description:

The CORDMILK Follow-up trial will examine the difference in survival and neurodevelopmental impairment of infants who were non-vigorous at birth and enrolled in the CORDMILK trial. The difference in survival and neurodevelopmental impairment in infants who received UCM and ECC will be assessed using standardized neurological and developmental assessment tools at 22-26 months of age.


Recruitment information / eligibility

Status Recruiting
Enrollment 3442
Est. completion date June 30, 2027
Est. primary completion date April 30, 2027
Accepts healthy volunteers No
Gender All
Age group 22 Months to 26 Months
Eligibility Inclusion Criteria: - Enrolled in CORDMILK trial - Non-vigorous at birth Exclusion Criteria: - None

Study Design


Intervention

Other:
Umbilical Cord Milking
At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.

Locations

Country Name City State
India KLE Academy of Higher Education and Research (Deemed-to-be-University) Jawaharlal Nehru Medical College Belgaum Karnataka
India Karnataka Institute of Medical Sciences Hubli Karnataka
India All India Institute of Medical Science Nagpur MS
India Daga Memorial Woman and Children Hospital Nagpur MS
India Government Medical College and Hospital Nagpur MS
India Indira Gandhi Government Medical College & Hospital Nagpur Maharashtra
India Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital Pune Maharashtra
India Mahatma Gandhi Institute of Medical Sciences/ Kasturba Hospital Wardha MS

Sponsors (14)

Lead Sponsor Collaborator
Nemours Children's Clinic All India Institute of Medical Science, Nagpur, India, Daga Memorial Maternity and Children's Hospital, Nagpur, India, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Government Medical College, Nagpur, Indira Gandhi Government Medical College & Hospital, Nagpur, India, Karnataka Institute of Medical Sciences, Hubbali, India, KLE Academy of Higher Education and Research (Deemed- to- be-University), Jawaharlal Nehru Medical College (JNMC), Belagavi, India, Mahatma Gandhi Institute of Medical Sciences/ Kasturba Hospital, Wardha, India, Pimpri Chinchwad Municipal Corporation's Post-Graduate Institute, Yashwantrao Chavan Memorial Hospital, Pune, India, Sharp HealthCare, St. Louis University, Thomas Jefferson University, University of California, San Diego

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neurodevelopmental Outcome at 2 Years of Age Neurodevelopmental assessment will be performed by the trained and experienced examiner who will be blinded to the interventions.
Severe neurodevelopmental impairment will be defined having at least one of the following: BSID (IV) composite cognitive score <70, GMFCS level 3-5, blindness (vision <20/200), or hearing impairment requiring hearing aids/cochlear implant. Moderate neurodevelopmental impairment will be defined as having a cognitive composite score 70-84, GMFCS level 2, unilateral blindness (vision/20/200 in only one eye), or hearing impairment with no amplification/cochlear implant.
22-26 months
Secondary Neurodevelopmental Outcome at 1 Year of Age Neurodevelopmental assessment will be performed by the trained and experienced examiner who will be blinded to the intervention using the Developmental Assessment Scales for Indian Infants (DASII). DAASI provides developmental motor quotient (DMoQ), developmental mental quotient (DMeQ), and composite developmental quotient (DQ). With a mean DQ of 100 and standard deviation (SD) of 15, 1SD and 2SD below mean correspond to DQ of 85 and 70, respectively. A DMoQ, DMeQ or DQ score of <70 (2SD) is considered as neurodevelopmental impairment. 10-14 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05048550 - Babies in Glasses; a Feasibility Study. N/A
Recruiting NCT05514340 - Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy Phase 2
Recruiting NCT05836610 - Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates Phase 4
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT01913340 - Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO) Phase 1/Phase 2
Enrolling by invitation NCT02260271 - Florida Neonatal Neurologic Network
Terminated NCT01192776 - Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE) N/A
Completed NCT06344286 - The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE N/A
Recruiting NCT05901688 - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting NCT02894866 - Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy N/A
Recruiting NCT03657394 - Comparative Outcomes Related to Delivery-room Cord Milking In Low-resourced Kountries N/A
Withdrawn NCT03681314 - Umbilical Cord Milking in Neonates Who Are Depressed at Birth-Developmental Follow Up (MIDAB-FU) N/A
Completed NCT03485781 - Propofol-induced EEG Changes in Hypoxic Brain Injury
Not yet recruiting NCT06429007 - A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury Phase 2
Recruiting NCT05568264 - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit N/A
Not yet recruiting NCT06448780 - Dose Optimization of Caffeine for HIE Phase 1
Completed NCT02264808 - Developmental Outcomes
Completed NCT05687708 - Effect of Non-nutritive Sucking on Transition to Oral Feeding in Infants With Asphyxia N/A
Recruiting NCT06195345 - Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)
Withdrawn NCT05295784 - PK and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia Phase 1